The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of DNA damage repair (DDR) mutations on treatment outcomes in men receiving conventional therapy for metastatic castration resistant prostate cancer (mCRPC).
 
Alex S. Carlson
No Relationships to Disclose
 
Rigo Acevedo
No Relationships to Disclose
 
Daniel M. Lim
No Relationships to Disclose
 
Roman Gulati
No Relationships to Disclose
 
Evan Y. Yu
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Clovis Oncology; Dendreon; Incyte; Janssen; Merck; Pharmacyclics; QED Therapeutics; Seagen
Research Funding - Daiichi Sankyo (Inst); Dendreon (Inst); Merck (Inst); Seagen (Inst); Taicho (Inst)
 
Michael Thomas Schweizer
Consulting or Advisory Role - Janssen
Research Funding - AstraZeneca (Inst); Janssen (Inst); Madison Vaccines, Inc. (Inst); Pfizer (Inst); Roche (Inst); Zenith Epigenetics (Inst)